Investigating the "steric gate" of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by targeted insertion of unnatural amino acids

Biochemistry

Volumn 46, Issue 8, 2007, Pages 2118-2126

  Klarmann, George J ^a   Eisenhauer, Brian M ^b   Zhang, Yi ^b   Gotte, Matthias ^c   Pata, Janice D ^d   Chatterjee, Deb K ^e   Hecht, Sidney M ^b   Le Grice, Stuart F J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOMETHYL-PHE115 RT; IMMUNODEFICIENCY; THIACYTIDINE TRIPHOSPHATE (3TCTP);

AMINO ACIDS; ENZYMES; ESCHERICHIA COLI; IMMUNOLOGY; SUBSTITUTION REACTIONS; SUBSTRATES;

VIRUSES;

AMINO ACID; BETA 2',3' DIDEOXY 3' THIACYTIDINE TRIPHOSPHATE; CYTIDINE PHOSPHATE; DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG TARGETING; ENZYME ASSAY; ENZYME KINETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MODEL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

AMINO ACID SUBSTITUTION; BINDING SITES; CELL-FREE SYSTEM; CYTIDINE TRIPHOSPHATE; DEOXYCYTOSINE NUCLEOTIDES; DNA; ESCHERICHIA COLI; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HYDROGEN BONDING; KINETICS; LAMIVUDINE; MODELS, MOLECULAR; PROTEIN BIOSYNTHESIS; PROTEIN ENGINEERING; REVERSE TRANSCRIPTASE INHIBITORS; TRANSCRIPTION, GENETIC; TYROSINE;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33847607579     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi061772w     Document Type: Article

References (39)

1. Telesnitsky, A., and Goff, S. P. (1997) In Retroviruses (Coffin, J. M., Hughes, S. H., and Varmus, H. E., Eds.) pp 121-160, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
2. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor, Science 256, 1783-1790.
3. Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Jr., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., Hizi, A., Hughes, S. H., and Arnold, E. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA, Proc. Natl. Acad. Sci. U.S.A. 90, 6320-6324.
4. Huang, H., Chopra, R., Verdine, G. L., and Harrison, S. C. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance, Science 282, 1669-1675.
5. Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H. (2000) Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase, Proc. Natl. Acad. Sci. U.S.A. 97, 3056-3061.
6. Martin-Hernandez, A. M., Gutierrez-Rivas, M., Domingo, E., and Menendez-Arias, L. (1997) Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115, Nucleic Acids Res. 25, 1383-1389.
7. Tisdale, M., Alnadaf, T., and Cousens, D. (1997) Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89, Antimicrob. Agents Chemother. 41, 1094-1098.
8. Martin-Hernandez, A. M., Domingo, E., and Menendez-Arias, L. (1996) Human immunodeficiency virus type 1 reverse transcriptase: Role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis, EMBO J. 15, 4434-4442.
9. Cases-Gonzalez, C. E., Gutierrez-Rivas, M., and Menendez-Arias, L. (2000) Coupling ribose selection to fidelity of DNA synthesis. The role of Tyr-115 of human immunodeficiency virus type 1 reverse transcriptase, J. Biol. Chem. 275, 19759-19767.
10. Larder, B. A., Kemp, S. D., and Purifoy, D. J. (1989) Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity, Proc. Natl. Acad. Sci. U.S.A. 86, 4803-4807.
11. Olivares, I., Sanchez-Merino, V., Martinez, M. A., Domingo, E., Lopez-Galindez, C., and Menendez-Arias, L. (1999) Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity, J. Virol. 73, 6293-6298.
12. Gao, G., and Goff, S. P. (1998) Replication defect of moloney murine leukemia virus with a mutant reverse transcriptase that can incorporate ribonucleotides and deoxyribonucleotides, J. Virol. 72, 5905-5911.
13. England, P. M. (2004) Unnatural amino acid mutagenesis: A precise tool for probing protein structure and function, Biochemistry 43, 11623-11629.
14. Dougherty, D. A. (2000) Unnatural amino acids as probes of protein structure and function, Curr. Opin. Chem. Biol. 4, 645-652.
15. Hendrickson, T. L., de Crecy-Lagard, V., and Schimmel, P. (2004) Incorporation of nonnatural amino acids into proteins, Annu. Rev. Biochem. 73, 147-176.
16. Sitaraman, K., Esposito, D., Klarmann, G., Le Grice, S. F., Hartley, J. L., and Chatterjee, D. K. (2004) A novel cell-free protein synthesis system, J. Biotechnol. 110, 257-263.
17. Klarmann, G. J., Eisenhauer, B. M., Zhang, Y., Sitaraman, K., Chatterjee, D. K., Hecht, S. M., and Le Grice, S. F. (2004) Site- and subunit-specific incorporation of unnatural amino acids into HIV-1 reverse transcriptase, Protein Expression Purif. 38, 37-44.
18. Ji, X., Klarmann, G. J., and Preston, B. D. (1996) Effect of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro, Biochemistry 35, 132-143.
19. Klarmann, G. J., Schauber, C. A., and Preston, B. D. (1993) Template-directed pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerization of HIV-1 sequences in vitro, J. Biol. Chem. 268, 9793-9802.
20. Klarmann, G. J., Smith, R. A., Schinazi, R. F., North, T. W., and Preston, B. D. (2000) Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site, J. Biol. Chem. 275, 359-366.
21. Boosalis, M. S., Petruska, J., and Goodman, M. F. (1987) DNA polymerase insertion fidelity. Gel assay for site-specific kinetics, J. Biol. Chem. 262, 14689-14696.
22. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination, Acta Crystallogr., Sect. D: Biol. Crystallogr. 54, 905-921.
23. Wilson, J. E., Aulabaugh, A., Caligan, B., McPherson, S., Wakefield, J. K., Jablonski, S., Morrow, C. D., Reardon, J. E., and Furman, P. A. (1996) Human immunodeficiency virus type-1 reverse transcriptase. Contribution of Met-184 to binding of nucleoside 5′-triphosphate, J. Biol. Chem. 271, 13656-13662.
24. Wilson, J. E., Porter, D. J., and Reardon, J. E. (1996) Inhibition of viral polymerases by chain-terminating substrates: A kinetic analysis, Methods Enzymol. 275, 398-424.
25. Reardon, J. E., and Miller, W. H. (1990) Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′-triphosphate, J. Biol. Chem. 265, 20302-20307.
26. Reardon, J. E. (1992) Human immunodeficiency virus reverse transcriptase: Steady-state and pre-steady-state kinetics of nucleotide incorporation, Biochemistry 31, 4473-4479.
27. Morales, J. C., and Kool, E. T. (1998) Efficient replication between non-hydrogen-bonded nucleoside shape analogs, Nat. Struct. Biol. 5, 950-954.
28. Kool, E. T. (2002) Active site tightness and substrate fit in DNA replication, Ann. Rev. Biochem. 71, 191-219.
29. Sarafianos, S. G., Das, K., Clark, A. D., Jr., Ding, J., Boyer, P. L., Hughes, S. H., and Arnold, E. (1999) Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids, Proc. Natl. Acad. Sci. U.S.A. 96, 10027-10032.
30. Patel, P. H., Jacobo-Molina, A., Ding, J., Tantillo, C., Clark, A. D., Jr., Raag, R., Nanni, R. G., Hughes, S. H., and Arnold, E. (1995) Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase, Biochemistry 34, 5351-5363.
31. Kunkel, T. A., and Bebenek, K. (2000) DNA replication fidelity, Annu. Rev. Biochem. 69, 497-529.
32. Morales, J. C., and Kool, E. T. (2000) Functional hydrogen-bonding map of the minor groove binding tracks of six DNA polymerases, Biochemistry 39, 12979-12988.
33. Beard, W. A., Osheroff, W. P., Prasad, R., Sawaya, M. R., Jaju, M., Wood, T. G., Kraut, J., Kunkel, T. A., and Wilson, S. H. (1996) Enzyme-DNA interactions required for efficient nucleotide incorporation and discrimination in human DNA polymerase β, J. Biol. Chem. 271, 12141-12144.
34. Meyer, A. S., Blandino, M., and Spratt, T. E. (2004) Escherichia coli DNA polymerase 1 (Klenow fragment) uses a hydrogen-bonding fork from Arg668 to the primer terminus and incoming deoxynucleotide triphosphate to catalyze DNA replication, J. Biol. Chem. 279, 3043-33046.
35. McCain, M. D., Meyer, A. S., Schultz, S. S., Glekas, A., and Spratt, T. E. (2005) Fidelity of mispair formation and mispair extension is dependent on the interaction between the minor groove of the primer terminus and Arg668 of DNA polymerase I of Escherichia coli, Biochemistry 44, 5647-5659.
36. Laws, W. R., and Brand, L. (1979) Analysis of two-state excited-state reactions. The fluorescence decay of 2-napthol, J. Phy. Chem. 83, 795-802.
37. Sarafianos, S. G., Das, K., Tantillo, C., Clark, A. D., Jr., Ding, J., Whitcomb, J. M., Boyer, P. L., Hughes, S. H., and Arnold, E. (2001) Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA, EMBO J. 20, 1449-1461.
38. Harris, D., Yadav, P. N., and Pandey, V. N. (1998) Loss of polymerase activity due to Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus type-1 reverse transcriptase is compensated by Met to Val substitution within the same motif, Biochemistry 37, 9630-9640.
39. Nunberg, J. H., Schleif, W. A., Boots, E. J., O'Brien, J. A., Quintero, J. C., Hoffman, J. M., Emini, E. A., and Goldman, M. E. (1991) Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors, J. Virol. 65, 4887-4892.